Sélectionner une page

Publications

 

  1. Bordeleau JM, Chouinard G, Tétreault L: Étude des propriétés hypnotiques d’une nouvelle benzodiazépine, le mogadon. Union Med Can 95: 45-50, 1966.
  2. Chouinard G, Ban TA, Lehmann HE, Ananth JV: Fluspirilene in the treatment of chronic schizophrenic patients. Curr Ther Res 12: 604-608, 1970.
  3. Chouinard G, Lehmann HE, Ban TA: Pimozide in the treatment of chronic schizophrenic patients. Curr Ther Res 12:598-603, 1970.
  4. Chouinard G, Pinard G, Prenoveau Y, Tetreault L: Alpha methyldopa-chlorpromazine interaction in schizophrenic patients. Curr Ther Res 15:60-72, 1973.
  5. Chouinard G, Ananth JV, Ban TA, Lehmann HE: Diphenylbutylpiperidines in the treatment of chronic schizophrenic patients. In: Les Diphenylbutylpipéridines, edited by A. Villeneuve, J.-M. Bordeleau. Québec Psychopharmacological Research Association, Les Presses de l’Université Laval, Québec, pp. 56-65, 1973.
  6. Chouinard G, Pinard G, Serrano M, Tetreault L: Potentiation of haloperidol by alphamethyldopa in the treatment of schizophrenic patients. Curr Ther Res 15:473-483, 1973.
  7. Chouinard G: Étude de l’association chlorpromazine-alphaméthyldopa chez le schizophrène. Thèse, Maîtrise en Sciences (Pharmacologie). Université de Montréal, février, 1974.
  8. Chouinard G, Annable L, Mélançon J, Chabot M: Chlorpromazine-induced electrocardiogram abnormalities. Int J Clin Pharmacol 11:327-331, 1975.
  9. Chouinard G, Annable L, Dubrovsky B, Dongier M: Post-imperative negative variation (PINV) in ambulatory schizophrenic patients. Compr Psychiatry 16:457-460, 1975.
  10. Chouinard G: Psychopharmacology in the elderly. Mod Med of Canada 30:127-128, 1975.
  11. Chouinard G: Pharmacotherapy and general management of depression. Mod Med of Canada 30:349-352, 1975.
  12. Chouinard G, Annable L, Serrano M, Albert J-M, Charette R: Amitriptyline- perphenazine interaction in ambulatory schizophrenic patients. Arch Gen Psychiatry 32: 1295-1307, 1975.
  13. Chouinard G: Schizophrénie et catécholamines. Union Med Can 104:885-889, 1975.
  14. Chouinard G: Emploi du carbonate de lithium en psychiatrie. In: Cahier Pédagogique II. La Problématique du Lithium, edited by C. Laurin. Département de Psychiatrie, Faculté de Médecine, Université de Montréal, pp. 80-85, June, 1975.
  15. Chouinard G, Fontaine R: Fluphenazine with other antipsychotic drugs (ltr to ed) Am J Psychiatry 132:760-761, 1975.
  16. Chouinard G, Annable L: Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. Am J Psychiatry 133:820-823, 1976.
  17. Chouinard G, Annable L: Clozapine in the treatment of newly admitted schizophrenic patients: A pilot study. J Clin Pharmacol 16:289-297, 1976.
  18. Chouinard G: Guide pratique pour l’emploi des agents psychopharmacologiques. I. Emploi de carbonate de lithium. Union Med Can 105:779-784, 1976.
  19. Chouinard G: More on fluphenazine and polypharmacy – Reply. (Letter to editor). Am J Psychiatry 133:105-106, 1976.
  20. Chouinard G: Reducing oral medication with depot fluphenazine – Reply. (Letter to Editor). Am J Psychiatry 133:585-586, 1976.
  21. Chouinard G: Guide pratique pour l’emploi des agents psychopharmacologiques. II. Antipsychotiques et antiparkinsoniens. Union Med Can 105:1387-1397, 1976.
  22. Chouinard G, Annable L: Alphamethyldopa-chlorpromazine combination in schizophrenic patients. Neuropsychobiology 2:118-126, 1976.
  23. Chouinard G, Annable L, de Montigny C, Kropsky M: Loxapine succinate in the treatment of newly admitted schizophrenic patients. Curr Ther Res 21:73-79, 1977.
  24. Chouinard G, Annable L, Dongier M: Differences in psychopathology of schizophrenic patients with normal and abnormal post-imperative negative variation (PINV). Compr Psychiatry 18:83-87, 1977.
  25. Chouinard G, Young SN, Annable L, and Sourkes TL: Tryptophan-nicotinamide in depression. (Letter to Editor). Lancet I:249, 1977.
  26. Chouinard G, Annable L, Serrano M, Charette R: A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients. Int Pharmacopsychiatry 12:1-8, 1977.
  27. Chouinard G, Annable L: The effect of a glucose load on phenothiazine-induced electrocardiographic abnormalities. Arch Gen Psychiatry 34:951-954, 1977.
  28. Chouinard G, Annable L, Kolivakis TNL: Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit. J Clin Pharmacol 17:162-167, 1977.

 

 

  1. Chouinard G, Annable L: Rubidium chloride in the treatment of schizophrenia. Communications in Psychopharmacology 1:373-383, 1977.
  2. Chouinard G, Annable L, Cooper S: Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic. Communications in Psycho-pharmacology 1:325-331, 1977.
  3. Chouinard G: La thérapie électro-convulsive dans le traitement de la dépression. Union Med Can 106:817-820, 1977.
  4. Chouinard G: Guide pratique pour l’emploi des agents psychopharmacologiques: III. Antidépresseurs. Union Med Can 106:821-828, 1977.
  5. Chouinard G, Annable L, Kropsky M: A double-blind controlled study of pipothiazine palmitate in the maintenance treatment of schizophrenic patients. J Clin Pharmacol 18:148-154, 1978.
  6. Chouinard G, Annable L, Ross-Chouinard A: A double-blind controlled study of fluphenazine decanoate and enanthate in the maintenance treatment of schizophrenic outpatients. In: Depot Fluphenazines: Twelve Years of Experience, edited by F.J. Ayd, Jr., Baltimore, Ayd Medical Communications, pp. 111-123, 1978.
  7. Chouinard G, Young SN, Annable L, Sourkes TL: Tryptophan dosage critical for its antidepressant effect (ltr to ed). Br Med J I:1422, 1978.
  8. Chouinard G, Annable L, Young SN, Sourkes TL: Tryptophan-benserazide in the treatment of schizophrenia. Communications in Psychopharmacology 2:21-31, 1978.
  9. Chouinard G: Book Review: Biological Foundations of Psychiatry, Volumes 1 & 2. Can Psychiatr Assoc J 23:124-125, 1978.
  10. Lesage J, Chouinard G: A case report of manic-depressive illness associated with Klinefelter’s syndrome and essential tremors. Father-to-son transmission (ltr to ed). Am J Psychiatry 135:757-758, 1978.
  11. Chouinard G: Les psychotropes en gériatrie. Le Médecin du Québec 13:90-91, 1978.
  12. Chouinard G, Jones BD: Schizophrenia as dopamine-deficiency disease. Lancet II:99-100, 1978.
  13. Chouinard G, Ghadirian AM, Jones BD: Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac-C capsule. Can Med Assoc J 119:729-731, 1978.
  14. Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 135:1409-1410, 1978.
  15. Chouinard G, Young SN, Annable L, Sourkes TL: Tryptophan-nicotinamide in the treatment of newly admitted depressed patients. Communications in Psychopharmacology 2:311-318, 1978.
  16. Chouinard G, Jones BD: Drug interaction studies in the support of schizophrenia as dopamine deficiency disease. Proceedings of the Founding Meeting of the Canadian College of Neuropsychopharmacology, edited by D.J. McClure, Montreal, pp.125-144, 1978.
  17. Chouinard G, Annable L, Ross-Chouinard A, Kropsky M: Ethopropazine and benztropine in neuroleptic-induced parkinsonism. J Clin Psychiatry 40:73-80, 1979.

46.Chouinard G, Annable L, Ross-Chouinard A, Nestoros JN: Factors related to tardive dyskinesia.  Am J Psychiatry 136:79-83, 1979.

  1. Chouinard G, Young SN, Annable L, Sourkes TL: Tryptophan-nicotinamide, imipramine and their combination in depression. Acta Psychiatr Scand 59:395-418, 1979.
  2. Chouinard G: Book Review: Annales de Therapeutique Psychiatrique, Vol. 5, par Henri Baruk. Paris: Presses Universitaires de France, 382, pp., 1974. Can Psychiatr Assoc J 24:94, 1979.
  3. Lesage J, Chouinard G: Sex chromosome anomalies and manic-depressive illness. Reply. (ltr to ed)  Am J Psychiatry 136:240, 1979.
  4. Chouinard G, Jones BD, Young SN, Annable L: Potentiation of lithium by tryptophan in a patient with bipolar illness. Am J Psychiatry 136:719-720, 1979.
  5. Chouinard G, Jones BD: Death attributed to ventricular arrhythmia (ltr to ed). Can Med Assoc J 120:1058-1060, 1979.
  6. Chouinard G, Annable L, Ross-Chouinard A: Facteurs reliés à la dyskinésie tardive. Union Med Can 108:356-373, 1979.
  7. Chouinard G, Jones BD: Early onset of tardive dyskinesia: a case report. Am J Psychiatry 136:1323-24, 1979.
  8. de Montigny C, Chouinard G Annable L: Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology 65:219-223, 1979.
  9. Chouinard G, Jones BD: Evidence of brain dopamine deficiency in schizophrenia. Can J Psychiatr 24:661-667, 1979.
  10. Chouinard G, de Montigny C, Annable L: Tardive dyskinesia and antiparkinsonian medication. Am J Psychiatr 136:228-229, 1979.
  11. Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatr 137:16-21, 1980.

 

 

  1. Chouinard G, Jones BD, Annable L: Neuroleptic-induced supersensitivity psychosis. In: Phenothiazines and Structurally Related Drugs: Basic and Clinical Studies, Developments in Neuroscience Volume 7, edited by E. Usdin, H. Eckert and I.S. Forrest, New York Elsevier North Holland, 1980.
  2. Chouinard G: Mise au point sur l’emploi du carbonate de lithium et les atteintes rénales et thyroïdiennes qui en découlent. Union Med Can 109:221-226, 1980.
  3. Chouinard G, Annable L, Jones BD, Ross-Chouinard A: Sex differences and tardive dyskinesia (ltr to ed). Am J Psychiatr 137:507, 1980.
  4. Chouinard G, Jones BD: Defining drug-induced supersensitivity (ltr to ed). Am J Psychiatry 137:992-993, 1980.
  5. Chouinard G, Denis JF: Anxiolytiques et hypnotiques. In: Manuel de Psychiatrie Clinique: Approche Contemporaine, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 703-721, 1980.
  6. Chouinard G, Denis JF: Les neuroleptiques. In: Manuel de Psychiatrie Clinique. Approche Contemporaine, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 723-741, 1980.
  7. Chouinard G, Denis JF: Les antidépresseurs. In: Manuel de Psychiatrie Clinique: Approche Contemporaine, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 743-753, 1980.
  8. Chouinard G, Denis JF: Le lithium. In: Manuel de Psychiatrie Clinique: Approche Contemporaine, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 755-766, 1980.
  9. Chouinard G, La sismothérapie, thérapie électroconvulsive. In: Manuel de Psychiatrie Clinique: Approche Contemporaine, edited by P. Lalonde and F. Grunberg, Chicoutimi (Québec), Gaétan Morin & Associés Ltée, pp. 767-775, 1980.
  10. Chouinard G, Jones BD: Anticholinergics and tardive dyskinesia. – Reply. (Letter to Editor). Am J Psychiatry 137:1470-1471, 1980.
  11. Chouinard G, Annable L, Olivier M, Fontaine F, Ross-Chouinard A: Psychotropic and neuropsychologic effects of piracetam in geriatric psychiatric patients: a controlled study. In “Proceedings of International Symposium on Nootropic Drugs”, Rio de Janeiro, Brazil, pp. 23-30, 1980.
  12. Young SN, Chouinard G, Annable L: Tryptophan in the treatment of depression. In “Serotonin: Current Aspects of Neurochemistry and Function”, edited by B. Haber, S. Gabay, M.R. Issidorides and SGA Alivisatos, New York, Plenum, pp. 727-737, 1981.
  13. Boisvert D, Chouinard G: Perspectives psychopharmacologiques. Le Médecin du Québec 16:79-85, 1981.
  14. Chouinard G: Book review: Haloperidol Update: 1958-1980. Ayd FJ (ed), Baltimore, Ayd Medical Communications, pp. 234, 1980. Can J Psychiatry 26(2):130-131, 1981.
  15. Chouinard G, Boisvert D: Lithium and regression of oat-cell carcinoma. (Letter to Editor). Can Med Assoc J 124:1555, 1981.
  16. Boisvert D, Chouinard G: Rebound cardiac arrhythmia after withdrawal from imipramine: a case report. Am J Psychiatry 138:985-986, 1981.
  17. Chouinard G, Annable L, Jones BD, Collu R: Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system. Acta Psychiat Scand 64:353-362, 1981.
  18. Chouinard G, Annable L, Langlois R: Absence of orthostatic hypotension in depressed patients treated with bupropion. Prog Neuro-Psychopharmacol 5:483-490, 1981.
  19. Chouinard G, Annable L, Collu R: Plasma prolactin levels: a psychiatric tool. In: Brain Peptides and Hormones. Collu R, Ducharme JR, Tolis G, Barbeau A (eds), Raven Press,  pp. 333-341, 1982.

77.Chouinard G, Annable L: Pimozide in the treatment of newly admitted schizophrenic patients.  Psychopharmacology 76:13-19, 1982.

  1. Chouinard G: Neuroleptic-induced supersensitivity psychosis. In: Tardive Dyskinesia and Related Involuntary Movement Disorders: The Long-Term Effects of Antipsychotic Drugs. DeVeaugh-Geiss J (ED), John Wright PSG of Boston, Massachusetts, pp.109-115, 1982.
  2. Chouinard G, Annable L. Ross-Chouinard A: Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect. Am J Psychiatry 139:312-318, 1982.
  3. Chouinard G, Bradwejn J: Reversible and irreversible tardive dyskinesia: a case report. Am J Psychiatry 139:3, 360-362, 1982.
  4. Chouinard G, Boisvert D, Bradwejn J: Tardive dyskinesia in a non-psychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. Can Med Assoc J 126:821-822, 1982.
  5. Chouinard G, Creese I, Boisvert D, Annable L, Bradwejn J, Jones B: High Neuroleptic Plasma Levels in Patients Manifesting Supersensitivity Psychosis. Biol Psychiatry 17:849-852, 1982.
  6. Young SN, Gauthier S, Chouinard G, Anderson GM, Purdy WC: The Effect of Carbidopa and Benzerazide on Human Plasma 5-Hydroxytryptophan Levels. J Neural Transmission 53:83-87, 1982.

 

 

  1. Chouinard G, Jones B: Neuroleptic-Induced Supersensitivity Psychosis, The ‘Hump Course’ and Tardive Dyskinesia. (Letter to Editor). J Clin Psychopharmacology 2:143-144, 1982.
  2. Ghadirian AM, Chouinard G, Annable L: Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis 170:463-467, 1982.
  3. Chouinard G, Annable L, Fontaine R, Solyom L: Alprazolam in the treatment of anxiety and panic disorders: A double-blind placebo-controlled study. Psychopharmacology 77:229-233, 1982.
  4. Belanger MC, Chouinard G: Technique for injecting long-acting neuroleptics. (Letter to Editor). Br J Psychiatry 141:316, 1982.
  5. Chouinard G, Steinberg S: Book review. Clinical Psychiatry in Primary Care. Can Med Assoc J 127:325, 1982.
  6. Chouinard G, Steinberg S: Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics. Prog Neuro-Psychopharmacol & Biol Psychiatr 6:571-578, 1982.
  7. Chouinard G, Young SN, Bradwejn J, Annable L: Tryptophan in the Treatment of Depression and Mania. In: Adv Biol Psychiat Vol. 10, pp. 47-66, Editors van Praag/Mendlewicz, Publisher S. Karger, Basel, 1983.
  8. Chouinard G, Young SN, Annable L: Antimanic Effect of Clonazepam. Biol Psychiatry 18:451-466, 1983.
  9. Chouinard G, Steinberg S: Schizophrenia. Medicine North America J 34:3172-3179, 1983.
  10. Chouinard G: Supersensitivity Psychosis. Hillside J Clin Psychiatry 4:131-140, 1983.
  11. Fontaine R, Annable L, Chouinard G, Ogilvie RI: Bromazepam and diazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. J Clin Psychopharmacol 3:80-87, 1983.
  12. Chouinard G, Annable L, Fontaine R, Solyom L: Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study. Psychopharmacol Bull 19:115-116, 1983.
  13. Chouinard G, Annable L: Fluspirilene in the treatment of newly admitted schizophrenic patients. Psychopharmacol Bull 19:136-138, 1983.
  14. Chouinard G, Annable L, Ross-Chouinard A, Olivier M, Fontaine F: Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment. Psychopharmacology 81: 100-106, 1983.
  15. Chouinard G: Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry 44:121-129, 1983.
  16. Mendels J, Amin MM, Chouinard G, Cooper AJ, Miles JE, Remick RA, Saxena B, Secunda SK, Singh AN: A comparative study of bupropion and amitriptyline in depressed outpatients. J Clin Psychiatry 44:118-120, 1983.

100.Chouinard G, Labonte A, Fontaine R, Annable L: New concepts in benzodiazepine therapy: rebound anxiety and new indications for the more potent benzodiazepines.  Prog Neuro Biol Psychiat 7: 669-673, 1983.

101.Chouinard G, Steinberg S: New clinical concepts on neuroleptic-induced supersensitivity disorders: tardive dyskinesia and supersensitivity psychosis.  In: Guidelines for the Use of Psychotropic Drugs. Edited by Stancer et al., S.P. Medical & Scientific Books, Spectrum Publications, Jamaica, N.Y., pp. 205-227, 1984.

102.Jones BD, Steinberg S, Chouinard G: Fast-cycling bipolar disorder induced by withdrawal from long-term treatment with a tricyclic antidepressant.  Am J Psychiatry 141:1, 108-109, 1984.

103.Fontaine R, Chouinard G, Annable L: Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment.  Am J Psychiatry 141:7, 848-852, 1984.

104.Chouinard G, Annable L, Bradwejn J: An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacology 83:126-128, 1984.

105.Fontaine R, Chouinard G: Antipanic effect of clonazepam. (Letter to Editor). Am J Psychiatry 141:149, 1984.

106.Fontaine R, Chouinard G, Annable L: Bromazepam and diazepam in generalized anxiety: a placebo-controlled study of efficacy and withdrawal. Psychopharmacol Bull 20: 126-127, 1984.

107.Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J: A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.  Psychopharmacol Bull 20: 108-109, 1984.

108.Beaudry P, Fontaine R, Chouinard G: Bromazepam, another high-potency benzodiazepine, for panic attacks.  (Letter to Editor).  Am J Psychiatry 141: 464-465, 1984.

109.Young SN, Chouinard G, Annable L, Morand C, Ervin FR: The therapeutic action of tryptophan in depression, mania and aggression. In: Progress in Tryptophan and Serotonin Research. Edited by Schlossberger HG, Kochen W, March/84 Linzen B, Steinhart H. Berlin, de Gruyter & Co, pp. 321-324, 1984.

110.Chouinard G: Benzodiazepine selection in clinical use. In: Benzodiazepine Therapy Today, Edited proceedings of a Canadian Symposium. Hollister L, Lapierre Y (eds).  Communications Media for Education, Princeton Jct., N.J., pp. 9-12, 1984.

111.Chouinard G: New pharmacological concepts in the treatment of anxiety disorders.  Editors’ Commentary. In: Focus/Psychiatric Practice. Communications Media for Education, Princeton Jct., N.J.. Vol 2, No 4, 1984.

112.Chouinard G, Bradwejn J, Annable L, Jones BD, Ross-Chouinard A: Withdrawal symptoms after long-term treatment with low potency neuroleptics. J Clin Psychiatry 45:500-502, 1984.

 

113.Chouinard G, Annable L: An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology 84:282-284, 1984.

  1. Chouinard G, Jones B: No cross-over of hypersensitivity reactions between zimelidine and fluoxetine. (ltr to ed) Can Med Assoc J 131:1190, 1984.

 

  1. Goldbloom D, Chouinard G: Clonazepan in the treatment of neuroleptic-induced somnambulism. (Letter to Editor). Am J Psychiatry 141:1486, 1984.
  2. Poiré-Salnave F, Bélanger M-C, Chouinard G: Le lithium – troisième révolution dans l’histoire de la maladie psychiatrique. L’infirmière canadienne 11:30-33, 1984.
  3. Judge G, Birrell M, Burke M, Chouinard G, Cipywnyk D, de Groot P, Johnson G, Martin G (Working-Group on Addiction Services): Addiction services in Hospitals. Guidelines for establishing standards for special services in hospitals. Report of the Sub-Committee on Special Services in Hospitals. National Health & Welfare, 1984.
  4. Fogel P, Mamer OA, Chouinard G, Farrell P: Determination of plasma bupropion and its relationship to therapeutic effect. Biomed Mass Spectrom 11:629-632, 1984.
  5. Chouinard G, Steinberg S: Schizophrenia. In: Readings in Psychiatry 3. Oxford: Medical Education Services, p. 1-5, 1984.
  6. Chouinard G, Annable L, Bradwejn J, Labonte A, Jones B, Mercier P, Bélanger M-C: An early Phase II clinical trial with follow-up of Tomoxetine (LY139603) in the treatment of newly admitted depressed patients. Psychopharmacol Bull 21:73-76, 1985.
  7. Fontaine R, Annable L, Beaudry P, Mercier P, Chouinard G: Efficacy and withdrawal of two potent benzodiazepines: bromazepam and lorazepam. Psychopharmacol Bull 21:91-92, 1985.
  8. Fontaine R, Chouinard G, Iny L: An open clinical trial of zimeldine in the treatment of obsessive compulsive disorder. Curr Ther Res 37:326-332, 1985.
  9. Jones B, Chouinard G: Clonazepam in the treatment of psychiatric symptoms associated with systemic lupus erythematosus. Am J Psychiatry 142: 354-355, 1985.
  10. Chouinard G: A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. J Clin Psychiatry 47:32-37, 1985.
  11. Chouinard G, Annable L, Campbell W, Boisvert D, Bradwejn J: A double-blind controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. Proceedings of the VIIth World Congress of Psychiatry, In Psychiatry: The State of the Art, Vol. 3. P. Pichot, P. Berner, R. Wolf, K. Thau (eds), Plenum Publishing Corp., pp. 759-761, 1985.
  12. Chouinard G, Young SN, Annable L: A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry 20:546-557, 1985.
  13. Goldbloom D, Chouinard G: Schizophreniform psychosis associated with chronic industrial toluene exposure. J Clin Psychiatry 46:350-351, 1985.
  14. Fontaine R, Chouinard G: Anti-obsessive compulsive effect of fluoxetine. (Letter to editor). Am J Psychiatry 142:989, 1985.
  15. Steinberg S, Chouinard G: A case of mania associated with tomoxetine. (Letter to Editor). Am J Psychiatry 142:1517-1518, 1985.
  16. Cohen BM, Waternaux C, Chouinard G, Sommer BR, Jones B: Plasma levels of neuroleptic in patients receiving depot fluphenazine. J Clin Psychopharmacol 5:328-332, 1985.
  17. Chouinard G: Antimanic effects of clonazepam. Psychosomatics (Supplement) 26(12):7-12, 1985.
  18. Fontaine R, Chouinard G: Fluoxetine in the treatment of obsessive compulsive disorder. Prog Neuro-Psychopharmacol & Biol Psychiatr 9:605-608, 1985.
  19. Chouinard G, Turnier L, Kallai-Sanfaçon M-A: Remoxipride in schizophrenia: effects on plasma prolactin. Prog Neuro-Psychopharmacol & Biol Psychiatr 9:599-603, 1985.
  20. Beaudry P, Fontaine R, Chouinard G, Annable L: An open clinical trial of clonazepam in the treatment of patients with recurrent panic attacks. Prog Neuro-Psychopharmacol & Biol Psychiatr 9:589-592, 1985.
  21. Chouinard G, McClure D, Nair NPV, Grof P, Max P, Merskey H, Westin JA: A Canadian multicenter clinical trial of zimelidine and amitriptyline in the treatment of patients with major depressive disorder. Selected papers from the 14th CINP Congress, Florence, Italy, 1984. In: Clinical and Pharmacological Studies in Psychiatric Disorders. Biological Psychiatry – New Prospects, Vol. 5. Burrows GD, Norman TR, Dennerstein L (eds). John Libbey & Company Ltd., London, England, pp. 66-71, 1985.
  22. Davidson JRT, Dren AT, Feighner JP, Ban T, Chouinard G: Multicenter study of a non-dopamine receptor blocking agent (BW 234U) in schizophrenia. Selected papers from the 14th CINP Congress, Florence, Italy, 1984. In: Clinical and Pharmacological Studies in Psychiatric Disorders. Biological Psychiatry – New Prospects, Vol. 5. Burrows GD, Norman TR, Dennerstein L (eds). John Libbey & Company Ltd., London, England, pp. 196-201, 1985.

 

 

  1. Beaudry P, Fontaine R, Chouinard G, Annable L: Clonazepam in the treatment of patients with recurrent panic attacks. J Clin Psychiatry 47:83-85, 1986.
  2. Chouinard G, Annable L, Steinberg S: A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 6:21-26, 1986.
  3. Fontaine R, Chouinard G: An open clinical trial of fluoxetine in the treatment of obsessive compulsive disorder. J Clin Psychopharmacol 6:98-101, 1986.
  4. Steiner W, Chouinard G: A case of mania induced by high-dose fluoxetine treatment. (Letter to editor). Am J Psychiatry 143:686, 1986.
  5. Chouinard G, Annable L, Mercier P, Ross-Chouinard A: A five-year follow-up study of tardive dyskinesia. Psychopharmacol Bull 22:259-263, 1986.
  6. Chouinard G: Use of clonazepam in the maintenance treatment of manic depressive illness. In: Biological Psychiatry 1985, Shagass C. et al. (eds), Elsevier Science Publishing Co., Inc., pp. 723-725, 1986.
  7. Chouinard G, Turnier L: An early Phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity. Psychopharmacol Bull 22:267-271, 1986.
  8. Chouinard G: Clonazepam in the treatment of mania and panic disorders. Publication subsequent to a symposium organized by the Royal Australian and New Zealand College of Psychiatrists in March 1986. Published by Excerpta Medica Asia Ltd, Hong Kong, p. 13, 1986.
  9. Chouinard G, Steiner W: Remoxipride in the treatment of acute mania. Biol Psychiatry 21:1429-1433, 1986.
  10. Chouinard G, Annable L, Ross-Chouinard A: Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. Psychopharmacol Bull 22:891-896, 1986.
  11. Fontaine R, Mercier P, Beaudry P, Annable L, Chouinard G: Bromazepam and lorazepam in generalized anxiety: a placebo controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 74:451-458, 1986.
  12. Chouinard G: Advances in the management of acute mania and bipolar manic-depressive illness. In: New Concepts in Mania and Panic Disorder: Focus on Clonazepam. (MEDICINE Publishing Foundation Symposium Series, 20). Toronto: MES Medical Education Services, pp. 1-14, 1986.
  13. Chouinard G: Rebound anxiety: incidence and relationship to subjective cognitive impairment. J Clin Psychiatry Monograph 4(1): 12-16, 1986.
  14. Chouinard G, Annable L, Mercier P, Turnier L: Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. Psychopharmacology Bull 23:221-226, 1987.
  15. Primeau F, Fontaine R, Chouinard G: Poorly controlled EPS: risk factors for NMS. (Letter to editor). Can J Psychiatry 32:328-331, 1987.
  16. Chouinard G: An early Phase II clinical trial of remoxipride in the treatment of schizophrenia with measurements of prolactin and neuroleptic activity. J Clin Psychopharmacol 7:159-164, 1987.
  17. Fontaine R, Beaudry P, Beauclair L, Chouinard G: Comparison of withdrawal of buspirone and diazepam: a placebo controlled study. Prog Neuro-Psychopharmacol & Biol Psychiatr 11:189-197, 1987.
  18. Cohen BM, Chouinard G, Waternaux C, Schachter H, Jones B, Sommer BR: Plasma concentration of neuroleptic and serum prolactin in patients chronically receiving depot fluphenazine: no evidence of tolerance. Human Psychopharmacology 2:171-176, 1987.
  19. Chouinard G: Clonazepam in acute and maintenance treatment of bipolar affective disorder. J Clin Psychiatry 48(10, Suppl):29-36, 1987.
  20. Laporta M, Chouinard G, Goldbloom, D, Beauclair L: Hypomania induced by sertraline, a new serotonin reuptake inhibitor. (Letter to Editor). Am J Psychiatry 144:1513-1514, 1987.
  21. Steinberg S, Steiner W, Chouinard G: Estrogen-progesterone combination: another mood stabilizer? (Letter to Editor). Am J Psychiatry 144:826, 1987.
  22. Langlois S, Kreeft JH, Chouinard G, Ross-Chouinard A, East S, Ogilvie RI: Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. Br J Clin Pharmacol 23:273-278, 1987.
  23. Germain L, Chouinard G: Treatment of recurrent unipolar major depression with captopril: 1 case report. Biol Psychiatry 23:637-641, 1988.
  24. Turnier L, Desrosiers P, Chouinard G: Prescrire un antipsychotique pour un problème gastro-intestinal: un risque pour le patient et pour le médecin. L’Actualité Médicale 9(9):26-29, 1988.
  25. Chouinard G: Clonazepam in the treatment of psychiatric disorders. In: Use of Anticonvulsants in Psychiatry: Recent Advances. Eds. McElroy SL, Pope HG, Oxford Health Care, Inc., Clifton, New Jersey, pp. 43-58, 1988.
  26. Beaudry P, Chouinard G: Defining the diagnosis of mania. Diagnosis 5:85-97, 1988.
  27. Chouinard G: Additional comments on benzodiazepine withdrawal. CMAJ 139:119-120, 1988.
  28. Chouinard G, Annable L, Ross-Chouinard A, Mercier P: A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. J Clin Psychopharmacol 8(4):21S-26S, 1988.

 

 

  1. Beauclair L, Chouinard G: Anxiolytiques et hypnotiques. In: Manuel de Psychiatrie Clinique: approche bio-psycho-sociale. Eds. P. Lalonde and F. Grunberg. Gaëtan Morin, Quebec, pp. 984-1007, 1988.
  2. Chouinard G, Beauclair L: Antipsychotiques. In: Manuel de Psychiatrie Clinique: approche bio-psycho-sociale. Eds. P. Lalonde and F. Grunberg. Gaëtan Morin, Quebec, pp. 1008-1037, 1988.
  3. Beauclair L, Chouinard G: Antidépresseurs et électroconvulsivothérapie. In: Manuel de Psychiatrie Clinique: approche bio-psycho-sociale. Eds. P. Lalonde and F. Grunberg.  Gaëtan Morin, Quebec, pp. 1038-1057, 1988.
  4. Chouinard G, Beauclair L: Stabilisateurs de l’humeur et antimaniaques. In: Manuel de Psychiatrie Clinique: approche bio-psycho-sociale. Eds. P. Lalonde and F. Grunberg.  Gaëtan Morin, Quebec, pp. 1058-1077, 1988.
  5. Chouinard G: The use of benzodiazepines in the treatment of manic depressive illness. J Clin Psychiatry 49(Suppl):15-19, 1988.
  6. Bélanger-Annable M-C, Chouinard G: Depression: A treatable illness? Eli Lilly Canada Inc., 1988.
  7. Germain L, Chouinard G: Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry 25:489-493, 1989.
  8. Fontaine R, Chouinard G: Fluoxetine in the long-term treatment of obsessive compulsive disorder. Psychiatric Annals 19:88-91, 1989.
  9. Turnier L, Desrosiers P, Chouinard G: Dyskinésie respiratoire induite par le retrait d’un antidopaminergique prescrit pour un problème digestif fonctionnel. Le clinicien 4:55-68, 1989.
  10. Chouinard G: La psychose de supersensibilité induite par les neuroleptiques. In: Dictionnaire des neuroleptiques. Colonna L, Petit M, Lépine JP (eds.), Éditions J.B. Baillière, Paris, pp. 295-298, 1989.
  11. Chouinard G, Annable L, Campbell W: A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. J Clin Psychopharm 9:247-253, 1989.
  12. Chouinard G: Clonazepam in treatment of bipolar psychotic patients after discontinuation of neuroleptics. Am J Psychiatry (Ltr to ed) 146:1642, 1989.
  13. Chouinard G: Recent advances in the treatment of depression. Report of a Symposia Series – Vancouver, Montreal, Toronto – May 1990, The Medicine Group, 1990.

178*.      Chouinard G, Beauclair L, Geiser R, Etienne P: A pilot study of magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients.  Prog Neuro-Psychopharmacol & Biol Psychiatry 14:171-180, 1990.

*Winner of 3rd Prize, Wyeth-Ayerst Award for New Research, North America, VIII World Congress of Psychiatry, Athens, Greece, October 12-19, 1989.

  1. Turnier L, Chouinard G, Desrosiers P: La dépression masquée. Le Médecin du Québec, pp. 93-96, mars 1990.
  2. Turnier L, Chouinard G: Effet anti-koro d’un antidépresseur tricyclique. Revue canadienne de psychiatrie 35:331-333, 1990.
  3. Desrosiers P, Turnier J, Hillel J, Chouinard G: Le diagnostic de la maladie bipolaire. Le Médecin du Québec, pp. 69-79, August 1990.
  4. Steiner W, Laporta M, Chouinard G: Neuroleptic-induced supersensitivity psychosis in patients with bipolar affective disorder. Acta Psychiatrica Scand 81(5):437-440, 1990.
  5. Sultan S, Chouinard G, Beaudry P: Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis. Prog Neuro-Psychopharmacol & Biol Psychiatry 14:431-438, 1990.
  6. Laporta M, Archambault D, Ross-Chouinard A, Chouinard G: Articulatory impairment associated with tardive dyskinesia. J Nerv and Men Disease 178:660-662, 1990.
  7. Chouinard G, Landry P: New drugs for the treatment of generalized anxiety, panic and obsessive-compulsive disorders. In: Handbook of Anxiety, Vol. 4: The Treatment of Anxiety. Edited by Noyes R. Jr., M. Roth and G.D. Burrows. Elsevier Science Publishers, B.V., pp. 271-289, 1990.
  8. Chouinard G, Beauclair L, Geiser R, Etienne P: Magnesium aspartate hydrochloride (Magnesiocard) as a mood stabilizer for rapid cycling bipolar affective disorder patients. In: Psychiatry: A world perspective. C.N. Stefanis et al., (eds), Elsevier Science Publishers B.V., Vol. 3, pp.368-376, 1990.
  9. Landry P, Chouinard G: Obsessive-compulsive disorder: Pathogenesis and fluoxetine treatment. Reviews in Contemporary Pharmacotherapy 1:61-74, 1990.
  10. Chouinard G, Sultan S: Treatment of supersensitivity psychosis with antiepileptic drugs: Report of a series of 43 cases. Psychopharmacology Bulletin 26:337-341, 1990.
  11. Chouinard G, A placebo-controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation. Acta Psychiatr Scand 82(Suppl.358):111-119, 1990.
  12. Teboul E, Chouinard G: A guide to benzodiazepine selection: Part I: Pharmacological aspects. Can J Psychiatry 35:700-710, 1990.
  13. Chouinard G, Goodman W, Greist J, Jenike M, Rasmussen S, White K, Hackett E, Gaffney M, Bick PA: Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacology Bulletin 26:279-284, 1990.
  14. Fontaine R, Beaudry P, Le Morvan P, Beauclair L, Chouinard G: Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. Int Clin Psychopharmacol 5: 173-183, 1990.
  15. Reimherr FW, Chouinard G, Cohn CK, et al: Antidepressant efficacy of sertraline: A double-blind, placebo- and amitriptyline-controlled multicenter comparison study in outpatients with major depression. J Clin Psychiatry 51(Suppl B):18-27, 1990.
  16. Chouinard G: Severe cases of neuroleptic-induced supersensitivity psychosis: Diagnostic criteria for the disorder and its treatment. Schizophrenia Research 5:21-33, 1990.
  17. Teboul E, Chouinard G: A guide to benzodiazepine selection. Part II: Clinical aspects. Can J Psychiatry 36:62-73, 1991.
  18. Landry P, Chouinard G, Primeau F: Lithium-tryptophan combination in the maintenance treatment of bipolar affective illness. Lithium 2:135-140, 1991.
  19. Chouinard G: Tryptophan and its role in the step-care approach to the treatment of affective disorders. The Canadian Review of Affective Disorders 1(2):1, 1991.
  20. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R: Response to steroid suppression in major depression resistant to antidepressant therapy. J Clin Psychopharmacol 11:121-126, 1991.
  21. Chouinard G: Fluoxetine and preoccupation with suicide (Ltr to ed). Am J Psychiatry 148:1258-1259, 1991.
  22. Chouinard G, Safadi G, Beauclair L: Zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. In: Biological Psychiatry Vol. 1, Proceedings of the 5th World Congress of Biological Psychiatry, Racagni G, Brunello N, Fukuda T (eds), Excerpta Medica, Amsterdam, pp. 560-562, 1991.
  23. Chouinard G: A double-blind, multicenter, placebo-controlled study of sertraline in obsessive-compulsive disorder. In: Biological Psychiatry Vol. 2, Proceedings of the 5th World Congress of Biological Psychiatry, Racagni G, Brunello N, Fukuda T (eds), Excerpta Medica, Amsterdam, p. 871, 1991.
  24. Bischoff S, Baumann P, Krauss J, Maitre L, Vassout A, Stroni A, Chouinard G: CGP 25454A, a novel and selective presynaptic dopamine autoreceptor antagonist. Naunyn Schmiedebergs Arch Pharmacol 350 (3) 230-8, 1994.
  25. Chouinard G, Sultan S: A case of Parkinson’s disease exacerbated by fluoxetine. Human Psychopharmacology 7:63-66, 1992.
  26. Murphy BEP, Dhar V, Ghadirian AM, Chouinard G, Keller R: Theoretical basis for response to steroid suppression in major depression – Reply. (Ltr to ed.) J Clin Psychopharmacol 12:143-144, 1992.
  27. Chouinard G: The emerging role of valproic acid in the therapy of bipolar disorder. Summary Proceedings of Satellite Symposium of the 41st Annual Canadian Psychiatric Association Meeting 1991, pp. 2-4, 1992.
  28. Chouinard G, Annable L: Risk factors in tardive dyskinesia and supersensitivity psychosis. In: Movement Disorders in Neurology and Neuropsychiatry. Edited by Joseph AB, Young RR, Boston, Blackwell Scientific Publications, Boston, pp. 51-59, 1992.
  29. Chouinard G: Sertraline in the treatment of obsessive compulsive disorder: Two double-blind, placebo-controlled studies. International Clinical Psychopharmacology 7(Suppl 2):37-41, 1992.
  30. Chouinard G, Saxena BM, Nair NP, Kutcher SP, Bakish D, Bradwejn J, Sharma V, Remick RA, Kukha-Mohamad SA: Efficacy of safety of brofaromine in depression: A Canadian multicentre placebo-controlled trial and a review of comparative contolled studies. Clinical Neuropharmacology 15 [Suppl] Pt A:426A-427A, 1992.
  31. Chouinard G, Jones BD, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W: A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 13:25-40, 1993.
  32. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, Beauclair L, Snaith J, D’Souza J: Brofaromine in depression: A Canadian multicenter placebo trial and a review of standard drug comparative studies. Clinical Neuropharmacology 16:S51-S54, 1993.
  33. Chouinard G, Annable L, Turnier L, Holobow N, Szkrumelak N: A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. Can J Psychiatry 38:(suppl. 4):S114-S121, 1993.
  34. Addington DE, Jones B, Bloom D, Chouinard G, Remington G, Albright P: Reduction of hospital days in chronic schizophrenic patients treated with risperidone. A retrospective study. Clin Ther 15(5):917-926, 1993.
  35. Chouinard G, Arnott W: Clinical Review of Risperidone. Can J Psychiatry 28:(suppl. 3):S89-S95, 1993.
  36. Miller R, Chouinard G: Loss of striatal cholinergic neurons as a basis of tardive and L-dopa-induced dyskinesias, and neuroleptic-induced supersensitivity psychosis. Biol Psychiatry 34:713-738, 1993.
  37. Chouinard G, Vainer JL, Bélanger M-C, Turnier L, Beaudry P, Roy J-Y, Miller R: Risperidone and clozapine in the treatment of drug-resistant schizophrenia or neuroleptic-induced supersensitivity psychosis. Prog Neuro-Psychopharmacology & Biol Psychiatry 18:1129-1141, 1994.
  38. Beauclair L, Fontaine R, Annable L, Holobow N, Chouinard G: Clonazepam in the treatment of panic disorder: A double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. J Clin Psychopharmacol 14:111-118, 1994.
  39. Chouinard G, Safadi G, Beauclair L: A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 14:377-384, 1994.
  40. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad SA, Bélanger M-C, Snaith J, Beauclair L, Pohlmann H, D’Souza J: A Canadian multicentre placebo-controlled study comparing a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treament of major depression. J Affective Disord 32:105-114, 1994.
  41. Vainer J, Chouinard G: Interaction between caffeine and clozapine. (Ltr to ed). J Clin Psychopharmacol 14:284-285, 1994.
  42. Brouillette M-J, Chouinard G, Lalonde R: Didanosine-induced mania in HIV infection. (Let to Ed.). Am J Psychiatry 151:1839-1840, 1994.
  43. Seeman P, Ulpian C, Chouinard G, Van Tol Hubert HM, Hy D, Lieberman JA, SIminovitch K, Liu ISC, Waye J, Voruganti P, Hudson C, Serjeant GR, Masibay AS, Seeman MV: Dopamine D4 Receptor Variant, D4GLYCINE194, in Africans but not in Caucasians: No association with schizophrenia. Am J Med G (Neuropsychiatric Genetics) 54:384-390, 1994.
  44. Reith J, Benkelfat C, Sherwin A, Yasuhara Y, Kuwabara H, Andermann F, Bachneff S, Cumming P, Diksic M, Dyve SE, Etienne P, Evans AC, Lal S, Shevell M, Savard G, Wong DF, Chouinard G, Gjedde A: Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci 91:11651-11654, 1994.
  45. Cunningham LA, Borison RL, Carman JS, Chouinard G, Crowder JE, Diamon BI, Fischer DE, Hearst E: A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 14:99-106, 1994.
  46. Chouinard G: Neuroleptiques: Spécificité d’action et association? Dans: Stratégies thérapeutiques à long terme dans les psychoses schizophréniques. Conférence de consensus. Textes des experts (chapitre de livre). Paris (France): Editions Frison-Roche, pp. 135-148, 1994.
  47. Mollër H-J, Müller H, Borison RL, Schooler NR, Chouinard G: A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study. Eur Arch Psychiatry Clin Neurosci 245:45-49, 1995.
  48. Ghadirian AM, Engelsmann F, Dhar V, Filipini D, Keller R, Chouinard G, Pearson Murphy BE: The Psychotropic Effects of Inhibitors of Steroid Biosynthesis in Depressed Patients Refractory to Treatment. Biol Psychiatry 37:369-375, 1995.
  49. Greist JH, Chouinard G, DuBoff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard RB, Rasmussen S, White K, Sikes C: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive compulsive disorder. Arch Gen Psychiatry 52:289-295, 1995.
  50. Nelson J, Chouinard G: Le trouble obsessionnel-compulsif n’est pas un trouble anxieux. Confrontations psychiatriques, 36:139-173, 1995.
  51. Chouinard G: Effects of risperidone in tardive dyskinesia: An analysis of the Canadian Multicenter Risperidone Study. J Clin Psychopharmacol 15:36S-44S, 1995.
  52. Chouinard G: Critique of the Canadian multicenter, placebo-controlled study of risperidone and haloperidol. Reply to DPrsP Musser and Kirisci. J Clin Psychopharmacol 15:226-230, 1995.
  53. Greist JH, Jefferson JW, Kobak KA, Chouinard G, Duboff E, Halaris A, Kim SW, Koran L, Liebowitz M, Lydiard B, Mcelroy S, Mendels J, Rasmussen S, White K, Flicker C: A one-year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 10:57-65, 1995.
  54. Ghadirian AM, Annable L, Bélanger M-C, Chouinard G: A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. J Clin Psychiatry 57:22-28, 1996.
  55. Nelson J, Chouinard G: Benzodiazepines: Mechanisms of Action and Clinical Indications. In: Brain Mechanisms and Psychotropic drugs. Eds. A Baskys and GJ Remington, CRC Press, Boca Raton, Florida, pp. 213-238, 1996.
  56. Chouinard G: Concomitant use of antipsychotics with risperidone. (Ltr to ed). Am J Health-Syst Pharm 53:(4)443, 1996.
  57. Nelson J, Chouinard G. Benzodiazepines: An update on their mechanisms of action. Can J Clin Pharmacol 3:(2)75-82, 1996.
  58. Chouinard G, Bélanger M-C, Beauclair L, Sultan S, Pearson-Murphy BE: Potentiation of fluoxetine by aminoglutethimide, a steroid suppressant, in obsessive-compulsive disorder resistant to SSRIs: A case report. Prog Neuro-Psychopharmacol and Biol Psychiat 20:(6)1067-1079, 1996.
  59. Lapierre YD, Joffe R, McKenna K, Bland R, Kennedy S, Ingram P, Reesal R, Rickhi BG, Beauclair L, Chouinard G, Annable L: Moclobemide versus Fluoxetine in the Treatment of Major Depressive Disorder in Adults. J Psychiatry Neurosci 22:118-126, 1997.
  60. Chouinard G, Albright PS: Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 18:298-307, 1997.
  61. Fournier JP, Lane RM, Chouinard G, Watson DB, Amin M, Remick RA, Thorpe LU: A double-blind comparison of sertraline and imipramine in outpatients with major depression: acute (8 weeks) and continuation (16 weeks) treatment. Human Psychopharmacology – Clinical and Experimental 12:203-215, 1997.
  62. Marder S, Davis JM, Chouinard G: The Effects of Risperidone on the Five Dimensions of Schizophrenia Derived by Factor Analysis: Combined Results of the North American Trial. Journal of Clinical Psychiatry 58:538-546, 1997.
  63. Chouinard G, Beauclair L, Bélanger M-C: Gabapentin: Long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Letter to Editor. Canadian Journal of Psychiatry 43:305, 1998.
  64. Dallal A, Chouinard G: Withdrawal or rebound symptoms associated with abrupt discontinuation of venlafaxine. Letter to Editor. J Clin Psychopharmacol 18:343-344, 1998.
  65. Looper KJ, Chouinard G: Beneficial effects of combined L-dopa and central anti-cholinergic in a patient with severe drug-induced parkinsonism and tardive dystonia. Letter to Editor. Canadian Journal of Psychiatry 43:646-647, 1998.
  66. Chouinard G, Kopala L, Labelle A, Beauclair L, Johnson SV, Singh KI, Ris-Can-3 Study Group: Phase IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. Canadian Journal of Psychiatry 43:1018-1025, 1998.
  67. Chouinard G, Annable L: Risk factors in tardive dyskinesia and supersensitivity psychosis. In: Drs. A.B. Joseph and R.R. Young (eds). Movement Disorders in Neurology and Neuropsychiatry. 2nd ed. Blackwell Scientific Publications, Boston, Chapter 6, p. 45, 1999.
  68. Margolese H, Chouinard G: Olanzapine-Induced Neuroleptic Malignant Syndrome in a patient with Mental Retardation. Letter to the Editor. American Journal of Psychiatry 156:1115-1116, 1999.
  69. Nelson J, Chouinard G: Guidelines for Clinical Use of Benzodiazepines: Pharmacokinetics, Dependency, Rebound, and Withdrawal. Canadian Journal of Clinical Pharmacology 6:69-83, 1999.
  70. Chouinard G, Saxena B, Bélanger M-C, Ravindran A, Bakish D, Beauclair L, Morris P, Nair NPV, Manchanda R, Reesal R, Remick R, O’Neill MC: A Canadian multicentre, double-blind study of paroxetine and fluoxetine in major depressive disorder. Journal of Affective Disorders 54:39-48, 1999.
  71. Chouinard G, Lefko-Singh K, Teboul E: Metabolism of anxiolytics and hypnotics: benzodiazepines, buspirone, zoplicone and zolpidem. Review. (Chapter) In: G.B. Baker (Guest Editor). Drug Metabolism and Psychiatry. Cellular and Molecular Neurobiology. Aug;19(4):533-552, 1999.
  72. Chouinard G, Miller R: A new Rating Scale for Psychotic Symptoms (RSPS). Part I. Theoretical Principles and Subscale 1: Perception Symptoms (Hallucinations and Illusions). Schizophrenia Research 38:101-122, 1999.
  73. Chouinard G, Miller R: A new Rating Scale for Psychotic Symptoms (RSPS). Part II. Subscale 2: Distraction Symptoms (Catatonia and Passivity Experiences). Subscale 3: Delusions and Semi-Structured Interview (SCI-RSPS). Schizophrenia Research 38:123-150, 1999.
  74. Ricard N, Sauriol L, Bélanger M-C, Chouinard G: Direct cost of psychiatric care in schizophrenic patients presenting in Emergency Unit: Retrospective Cohort Study. Psychiatric Services 50:(10):1287-1288, 1999.
  75. Beauclair L, Radoi-Andraous D, Chouinard G: Selective Serotonin/Noradrenaline Reuptake Inhibitors (SNRIs). (Chapter). In: Benjamin J. Sadock, Virginia A. Sadock (eds). Kaplan & Sadock’s Comprehensive Textbook of Psychiatry, Seventh Edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2000, Vol. 2, no. 31.24, p. 2427-2432.
  76. Versiani M, Amin M, Chouinard G: A double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. Journal of Clinical Psychopharmacology 20:28-34, 2000.
  77. Margolese HC, Chouinard G: Serotonin Syndrome From Addition of Low-Dose Trazodone to Nefazodone (letter). American Journal of Psychiatry, 157:1022, 2000.
  78. Barsoum A, Kolivakis TT, Margolese HC, Chouinard G: Diphenhydramine (Unisom®, Benadryl®), a Central Anticholinergic and Antihistaminic, Abuse with Massive Ingestion in a Patient with Schizophrenia. Letter to Editor. Canadian Journal of Psychiatry 45:846-847, 2000.
  79. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Barr Taylor C, Dager SR, Shiovitz T: Placebo-Controlled Study of Gabapentin Treatment of Panic Disorder. Journal of Clinical Psychopharmacology 20:467-471, 2000.

 

 

  1. Margolese HC, Chouinard G, Beauclair L, Rubino M: Cutaneous vasculitis induced by the selective serotonin reuptake inhibitor paroxetine in a patient with obsessive-compulsive disorder. Letter to Editor. American Journal of Psychiatry 158:497, 2001.
  2. Beauclair L, Chouinard G: Stabilisateurs de l’humeur. (Chapter) In: P. Lalonde, J. Aubut, F. Grunberg, and coll. (eds). Psychiatrie Clinique. Une approche bio-psycho-sociale. Tome II: Spécialités, traitements, sciences fondamentales et sujets d’intérêt. Gaëtan Morin, Boucherville, Quebec, Canada, 2001, Chapter 45, p. 1205-1225.
  3. Margolese HC, Chouinard G, Walters Larach V, Beauclair L: Relationship between antipsychotic-induced akathisia and tardive dyskinesia and suicidality in schizophrenia: impact of clozapine and olanzapine. Acta Psychiatrica Belgica 101:128-144, 2001.
  4. Kolivakis TT, Margolese HC, Beauclair L, Chouinard G: Olanzapine-Induced Somnambulism In Patients with Schizophrenia. Letter to Editor. American Journal of Psychiatry 158:1158, 2001.
  5. Miller R, Chouinard G: Les médicaments antipsychotiques: Évolution ou Révolution?, In: Jean-Pierre Olié, Jean Daléry, Jean-Michel Azorin (ed.). III. Médicaments antipsychotiques et situations pathologiques. «Les troubles schizoaffectifs. Typologie unidimensionnelle et principes thérapeutiques», (Chapter). ETICOM-Acanthe, Paris, France, 2001 pp. 397-412.
  6. Kolivakis TT, Margolese HC, Beauclair L, Chouinard G: Clozapine for First-Episode Schizophrenia. Letter to Editor. American Journal of Psychiatry 159:317, 2002.
  7. Dion Y, Annable L, Sandor P, Chouinard G: Risperidone in the treatment of Tourette Syndrome: A double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 22:31-39, 2002.
  8. Margolese HC, Chouinard G, Beauclair L, Bélanger M-C: Therapeutic Tolerance and Rebound Psychosis during Quetiapine Maintenance Monotherapy in Patients with Schizophrenia and Schizoaffective Disorder. Journal of Clinical Psychopharmacology 22:347-352, 2002.
  9. Margolese HC, Chouinard G, Beauclair L, Miller R: Using the Rating Scale for Psychotic Symptoms to Characterize Delusions Expressed in a Schizophrenia Patient With “Internet Psychosis”. Letter to Editor. Canadian Journal of Psychiatry 47:485, 2002.
  10. Levy E, Margolese HC, Chouinard G: Topiramate produced weight loss following olanzapine induced weight gain in schizophrenia. Letter to Editor. Journal of Clinical Psychiatry 63:1045, 2002.
  11. Jablonowski K, Margolese HC, Chouinard G: Gabapentin-induced paradoxical exacerbation of psychosis in a patient with schizophrenia. Letter to Editor. Canadian Journal of Psychiatry 47:975-976, 2002.
  12. Bhanji N, Margolese HC, St-Laurent M, Chouinard G: Dysphoric mania induced by high-dose mirtazapine: a case for “norepinephrine syndrome”? International Clinical Psychopharmacology 17:319-322, 2002.
  13. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A; Bourgeois M; Chouinard G, Islam MZ, Kane J, Krishnan R; Lindenmayer JP; Potkin S: Clozapine Treatment for Suicidality in Schizophrenia International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 60:82-91, 2003.
  14. Margolese HC, Beauclair L, Szkrumelak N, Chouinard G: Hypomania Induced by Adjunctive Lamotrigine. Letter to Editor. American Journal of Psychiatry 160:1, 2003.
  15. Bhanji N, Margolese HC, Chouinard G, Turnier L: Late-Onset Agranulocytosis in a Patient With Schizophrenia After 17 Months of Clozapine Treatment. Letter to Editor. Journal of Clinical Psychopharmacology 23:522-523, 2003.
  16. Chouinard G: Issues in the Clinical Use of Benzodiazepines. Journal of Clinical Psychiatry, Supplement Preview 64:5-7, 2003.
  17. Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris P, Breier A: Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety During the First 24 Hours of Treatment. Can J Psychiatry 48:716-721, 2003.
  18. Levy E, Margolese H, Sultan S, Chouinard G: Obsessive-Compulsive Symptoms in Schizophrenia Induced by Risperidone and Responding to Fluoxetine. (Letter to editor). Can J Psychiatry 48:709-710, 2003.
  19. Margolese HC, Chouinard G, Beauclair L, Bélanger M-C: Therapeutic Tolerance to Quetiapine: Response to Drs. Goldstein and Macfadden. Letter to the Editors. Journal of Clinical Psychopharmacology 24:103-104, 2004.
  20. Bhanji N, Chouinard G, Margolese HC: A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. European Neuropsychopharmacology 14:87-92, 2004.
  21. Kolivakis TT, Beauclair L, Margolese HC, Chouinard G: Long-term adjunctive lamotrigine to antipsychotic monotherapy in schizophrenia, further evidence. Letter to the Editor. Can J Psychiatry 49:280, 2004.
  22. Chouinard G: Considerations in Developing Criteria for Drug Induced Movement Posture Disorder: Tardive Dyskinesia. Journal of Clinical Psychiatry, Visuals:2-4, March 2004.
  23. Chouinard G: Issues in the Clinical Use of Benzodiazepines: Potency, Withdrawal, and Rebound. Journal of Clinical Psychiatry: 65 (Suppl 5) 7-12, 2004.
  24. Chouinard G: Le traitement pharmacologique du patient difficile et de la dangerosité. Les dangerosités de la criminologie à la psychopathologie, entre justice et psychiatrie. Éditions John Libbey Eurotext, sous la direction de Christiane de Beaurepaire, Michel Bénézech, Christian Kottler, Paris, France, 2004, Traitement de la dangerosité, p. 325-334.
  25. Chouinard G: New Nomenclature for Drug-Induced Movement Disorders Including Tardive Dyskinesia. Journal of Clinical Psychiatry: 65 (Suppl 9) 9-15, 2004.
  26. Corruble E, Awad H, Chouinard G, Hardy P: ECT in Delusional Depression Associated with Multiple Sclerosis. Am J Psychiatry 161: 1715, 2004.
  27. Levy E, Margolese HC, Annable L, Chouinard G: Diabetes and Tardive Dyskinesia, Parkinsonism, Akathisia in Schizophrenia: A Retrospective Study Applying 1998 Diabetes Health Care Guidelines to Antipsychotic Use. Can J Psychiatry 49:215-219, 2004.
  28. Alphs L, Anand R., Islam MZ, Meltzer HY, Kane J, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R: The International Suicide Prevention Trial (InterSePT): Rationale and Design of a Trial Comparing the Relative Ability of Clozapine and Olanzapine to Reduce Suicidal Behavior in Schizophrenic and Schizoaffective Patients. Schizophrenia Bulletin 2004; 30(3):577-86.
  29. Esposito D, Corruble E, Hardy P, Chouinard G: Risperidone-Induced Morning Pseudoneutropenia. Let to Ed. Am J Psychiatry 162:397, 2005.
  30. Bhanji N, Chouinard G, Hoffman L, Margolese HC. Seizures, Coma, and Coagulopathy following Olanzapine Overdose. Can J Psychiatry, 50:126-127, 2005.
  31. Margolese H, Chouinard G, Kolivakis T, Beauclair L, Miller R: Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics (Part 1): Pathophysiology and Mechanisms of Induction. Can J Psychiatry 50:541-547, 2005.
  32. Chouinard G, Margolese HC: Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophrenia Research 76:247-265, 2005.
  33. Pfeffer G, Chouinard G, Margolese HC: Gabapentin in the Treatment of Antipsychotic-Induced Akathisia in Schizophrenia. International Clinical Psychopharmacology 20(3):179-181, 2005.
  34. Gharabawi GM, Bossie CA, Lasser RA, Turkoz I, Rodriguez S, Chouinard G: Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-Scale Comparison in Assessing Tardive Dyskinesia. Schizophrenia Research 77:119-128, 2005.
  35. Corruble E, Chouinard G: Differences between second-generation antidepressants? Rapid response. Ann Inter Med, 2005
  36. Margolese H, Chouinard G, Kolivakis T, Beauclair L, Miller R, Annable L: Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics (Part 2): Incidence and Management Strategies in Patients with Schizophrenia. Can J Psychiatry 50:541-547, 2005.
  37. Esposito D, Brocvielle H, Becquemont L, Chouinard G, Hardy P, Corruble E: Risperidone-Induced Immunoallergic Hepatitis. Let to Ed. Am J Psychiatry 162(10):1984, 2005.
  38. Esposito D, Chouinard G, Hardy P, Corruble E: Successful initiation of clozapine treatment despite morning pseudoneutropenia. Int J Neuropsychopharmacol: Aug; 9(4):489-91.[Epub2005 Sep28, 1-3, 2005 ] 2006.
  39. Corruble E, Buhl C, Esposito D, Schuster JP, Chouinard VA, Hardy P, Chouinard G: Psychosis Associated with Elevated Trough Tacrolimus Blood Concentrations after joint combined kidney and pancreas transplantation, treated with olanzapine. Let to Ed. Int J Neuropsychopharmacol Aug;9(4) :493-4 [2005 Nov 29;:1-2 Epub ], 2006.
  40. Bhanji N, Chouinard G, Kolivakis T, Margolese HC: Persistent Tardive Rebound Panic Disorder, Rebound Anxiety and Insomnia following Paroxetine Withdrawal: A review of rebound-withdrawal phenomena. Can J Clin Pharmacol 13 (1): e69-e74, 2006.
  41. Chouinard G: The Search for New Off Label Indications for Antidepressant, Antianxiety, Antipsychotic and Anticonvulsant Drugs: Part 1: Heinz Lehmann Award 2004. J Psychiatry Neurosci 31(3) :168-176, 2006.
  42. Chouinard G: Inter-relationships Between Psychiatric Symptoms and Drug-Induced Movement Disorder (DIMD): Part 2: Heinz Lehmann Award 2004. J Psychiatry Neurosci 31(3) :177-180, 2006.
  43. Schuster JP, Buhl C, Archambaud F, Hardy P, Chouinard G, Prigent A, Corruble E. Using striatal dopamine transporter single photon emission computed tomography imaging to rule out Dementia with Lewy Bodies in elderly patients with antipsychotic-induced parkinsonism. Psychiatry Clin Neurosci 61(2):206, 2007
  44. Buhl C, Riaux A, Andraud F, Chouinard G, Hardy P, Corruble E. Nine-year prophylactic maintenance electroconvulsive therapy in an 89-year-old woman with recurrent psychotic major depressive disorder. Am J Geriatr Psychiatry 15(4):357, 2007.
  45. Lévy E, Agbokou C, Ferreri F, Chouinard G, Margolese HC. Topiramate-induced weight loss in schizophrenia: a retrospective case series study. Can J Clin Pharmacol 14(2):234-9, 2007
  46. Chouinard G, Chouinard VA. Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes. Psychother Psychosom 77(2): 69-77, 2008.
  47. Peretti CS, Ferreri F, Blanchard F, Bakchine S, Peretti CR, Dobrescu A, Chouinard VA, Chouinard G.Normal and pathological aging of attention in presymptomatic Huntington’s, Huntington’s and Alzheimer’s Disease, and nondemented elderly subjects. Psychother Psychosom 77(3): 139-46, 2008.
  48. Breil F, Verstuyft C, Orostegui L, Buhl C, Alvarez JC, Chouinard G, Becquemont L, Corruble E. Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. Int J Neuropsychopharmacol 11(5): 727-8, 2008.
  49. Corruble E, Chouinard VA, Letierce A, Gorwood P, Chouinard G: DSM Bereavement Exclusion for Major Depression is not Relevant to Severity and Pattern of Symptoms. J Clin Psychiatry 70 (8): 1091-7, 2009.
  50. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S, Eriksson H: Extended release quetiapine fumarate (quetiapine XR) :a once a day monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropschopharmacol 13(3): 305-320, 2010.
  51. Corruble E, Gorwood PA, Chouinard G: V Code for Bereavement Paula Clayton Reply. J Clin Psychiatry 71(3): 360, Mar 2010.
  52. Demily C, Chouinard VA, Chouinard G: Reconnaître les symptômes psychiatriques iatrogènes liés aux antipsychotiques. L’Encéphale 36 :417-424, 2010.
  53. Chouinard G, Chouinard VA, Corruble E: Beyond DSM-IV Bereavement Exclusion Criterion E for Major Depressive Disorder. Psychother Psychosom (Epub Oct 23; 80(1) 4-9 2010) 80: 804-9, 2011.
  54. JM Cloos, R Stein, P Rauchs, P Koch, G Chouinard: Addictions aux benzodiazépines: prévalence, diagnostic et traitement. Encyclopédie Médico Chirurgicale. EMC (Elsevier Masson SAS, Paris) Psychiatrie, 37-396-A-17, 2011.
  55. Peretti CS, Peretti CR, Kozora E, Papathanassiou D, Chouinard VA, Chouinard G: Cognitive Impairment in Systemic Lupus Erythematosus Women with Elevated Autoantibodies and Normal Single Photon Emission Computerized Tomography. Psychother Psychosom, Jul 20; 81(5):276-285. [Epub ahead of print] 2012.
  56. Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient Online Report of Selective Serotonin Reuptake Inhibitor (SSRI) Induced Persistent Postwithdrawal Anxiety and Mood Disorders. Psychother Psychosom 81: 386-388, 2012.
  57. Fava GA, Tossani E, Bech P, Berrocal C, Chouinard G, Csillag C, Wittchen HU, Rief W: Emerging Clinical Trends and Perspectives on Comorbid Patterns of Mental Disorders in Research. Int J Methods Psychiatr Res 23 Suppl 1: 92-101, 2014.
  58. Wittchen HU, Knappe S, Andersson G, Araya R, Banos Rivera RM, Barkham M, Bech P, Beckers T, Berger T, Berking M, Berrocal C, Botella C, Carlbring P, Chouinard G, Colom F, Csillag C, Cujipers P, David D, Emmelkamp PM, Essau CA, Fava GA, Goschke T, Hermans D, Hofmann SG, Lutz W, Muris P, Ollendick TH, Raes F, Rief W, Riper H, Tossani E, van der Oord S, Vervliet B, Haro JM, Schumann G : Roadmap for Mental Health Research in Europe (Roamer) The need for a behavioural science focus in research in mental health and mental disorders. Int J Methods Psychiatr Res.; 23 Suppl 1:28-40, 2014.
  59. Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent Postwithdrawal Disorders Induced by Paroxetine, a Selective Serotonin Reuptake Inhibitor (SSRI), and Treated by Specific Cognitive Behavioral Therapy (CBT). Psychother Psychosom 83(4): 247-248, 2014.
  60. Chouinard G, Chouinard VA: New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal. Psychother Psychosom 84(2): 63-71, 2015.
  61. Cloos JM, Bocquet V, Rolland I, Koch P, Chouinard G: Hypnotics and Triazolobenzodiazepines- Best predictors of High-Dose Benzodiazepine Use: Results from the Luxembourg National Health Insurance Registry. Psychother Psychosom 84(5): 273-283, (6 August pub online) 2015.
  62. Chopin MV, Peretti CS, Gisquet-Verrier P, Hoffmann C, Belaïd A, Chouinard G : Cocaine Use Disorder Treated with Specific Cognitive Behavioral Therapy and Adjunctive Propranolol. Psychother Psychosom 85(1) :61-63 (pub online November 27,2015) 2016
  63. Chouinard VA, Pingali SM, Chouinard G, Henderson DC, Mallya SG, Cypess AM, Cohen BM, Öngür D: Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar Disorders. Psychiatry Research 237: 304-310, 2016. http://dx.doi.org/10.1016/j.psychres.2016.01.024i.
  64. Bech P, Peuskens JC, Marder SR, Chouinard G, Høyberg OJ, Huttunen MO,Blin O, et al. Meta-analytic study of the benefits and risks of treatingchronic schizophrenia with risperidone or conventional neuroleptics. Eur Psychiatry 1998; 13:310-4.
  65. Virginie-Anne Chouinard, Sang-Young Kima, Linda Valeri, Cagri Yuksel, Kyle P. Ryan, Guy Chouinard, Bruce M. Cohen, Fei Dua, Dost Öngür. Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders Schizo Research Sept 2017;187: 11-16.

 

  1. Guy Chouinard, Anne-Noël Samaha, Virginie-Anne Chouinard, Charles-Siegfried Peretti, Nobuhisa Kanahara, Masayuki Takase, Masaomi Iyo. Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria and Therapy. Psychother Psychosom 2017;86: 189–219 DOI: 10.1159/000477313 [Epub ahead of print] PMID: 28647739 [PubMed – as supplied by publisher].
  2. Cosci F, Chouinard Guy, Chouinard VA, Fava GA. The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability Riv Psichiatr. 2018 Mar-Apr;53(2):95-99.
  3. Richard Balon, Guy Chouinard, Fiammetta Cosci et al. International Task Force on Benzodiazepines Psychother Psychosom 2018; 87:193–194.
  4. Nardi AE, Cosci F, Balon R, Weintraub SJ, Freire RC, Krystal JH, Roth T, Silberman EK, Sonino N, Fava GA, Starcevic V, Dubovsky SL, Salzman C8, Rickels K, Greenblatt DJ, Shader RI, Chouinard G; International Task Force on Benzodiazepines. The Prescription of Benzodiazepines for Panic Disorder: Time for an Evidence-Based Educational Approach. J Clin Psychopharmacol. 2018 Aug;38(4):283-285.
  5. Cosci F, Chouinard G. The monoamine hypothesis of depression revisited: could it mechanistically novel antidepressant strategies? In: Neurobiology of depression: road to novel therapeutics. Ed. Quevedo J, Carvalho AF, Zarate CA; Elsevier, 2019; pp. 63-73.
  6. Peretti CS, Chouinard G: Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis. Psychother Psychosom. Psychother Psychosom. 2019 ; 88(5):313-314. doi : 10.1159/000501130. Epub 2019 Jul 10. PMID : 31291629
  7. Cosci F, Nardi AE, Starcevic V, Chouinard G, Balon R. Lormetazepam in oral solution: a formulation at risk of high-dose use. Intern Emerg Med. 2019 Nov;14(8):1203-1204. doi: 10.1007/s11739-019-02143-y. Epub 2019 Jul 3. PMID: 31270679
  8. Davies J, Read J, Hengartner MP, Cosci F, Fava G, Chouinard G, van Os J, Nardi A, Gøtzsche P, Groot P, Offidani E, Timimi S, Moncrieff J, Spada M, Guy A. Clinical guidelines on antidepressant withdrawal urgently need updating. BMJ. 2019 May 20;365: l2238. doi: 10.1136/bmj.l2238. PMID: 31109968.
  9. Cosci F, Chouinard G. Acute and Persistent Withdrawal Syndromes Following. Discontinuation of Psychotropic Medications Psychother Psychosom 2020 August ;89(5):283-306. Apr 7: 1-24. doi: 10.1159/000506868. [Epub ahead of print] Review.PMID: 32259826.
  10. Cosci F, Romanazzo S, Manseuto G, Rontani P, Levitan MNᵈ, Cunha Dias da Rocha D, Halkjœr-Lassen RD, Quagliato LA, Nakamura T, Uematsu K, Nardi AE, Oe M, Chouinard VA, Chouinard G. Clinical utility of semi-structured interview and scales to assess withdrawal syndromes with dose reduction or discontinuation of Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reuptake Inhibitors. J Clin Psychopharmacol 2022 Jan-Feb 01;42(1): 17:22. doi: 10.1097/JCP.0000000000001491.PMID 34928557.
  11. Cosci F, Chouinard V-A, Chouinard G. When Withdrawal Symptoms Change the Meaning of Research Data Psychother Psychosom. 2022 Mar 21;1-2. doi: 10.1159/000522241. PMID: 35313311 DOI: 10.1159/000522241
  12. Cosci F, Chouinard V-A, Chouinard G. Discontinuation of antidepressant medications, a significant healthcare problem insufficiently addressed by the NICE guidelines. Psychother Psychosom. 2023;92(3):148-151. doi: 10.1159/000530692. Epub 2023 May 24. PubMed PMID: 37231914
  13. Chouinard G, Cosci F, Chouinard VA, Alphs L. The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties. Psychother Psychosom. 2023;92(6):359-366. doi: 10.1159/000535113. Epub 2023 Dec 7. Review. PubMed PMID: 38061344
  14. Davies J, Read J, Kruger D, Crisp N, Lamb N, Dixon M, Everington S, Hollins S, Moncrieff J, Giurca BC, van Tulleken C, Chouinard G, Dooley M, Guy A, Horowitz M, Kinderman P, Johnstone L, Montagu L, Nardi AE, Stacey S, Bell M, Tresidder A, Watson J, Lewis S, Spada M, Payne R, Akhtar N, Buckland C, Levett J, Whitcombe S, Marshall-Andrews L. Politicians, experts, and patient representatives call for the UK government to reverse the rate of antidepressant prescribing. BMJ. 2023 Dec 5;383:2730. doi: 10.1136/bmj.p2730. PubMed PMID: 38052460

336.Cosci F, Chouinard V-A, Chouinard G. Selective Serotonin Reuptake Inhibitor and Serotonin-Noradrenaline Reuptake Inhibitor Withdrawal Changes DSM Presentation of Mental Disorders: Results from the Diagnostic Clinical Interview for Drug Withdrawal. Psychother Psychosom. 2024;93(5):340-345. doi: 10.1159/000540031. Epub 2024 Jul 23.PMID: 39043160